Bicara Therapeutics BCAX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's retained earnings?
- Bicara Therapeutics (BCAX) reported retained earnings of -$415.18M in Q1 2026.
- How has Bicara Therapeutics's retained earnings changed year-over-year?
- Bicara Therapeutics's retained earnings decreased by 61.0% year-over-year, from -$257.86M to -$415.18M.
- What is the long-term trend for Bicara Therapeutics's retained earnings?
- Over 2 years (2023 to 2025), Bicara Therapeutics's retained earnings has grown at a 53.2% compound annual growth rate (CAGR), from -$153.02M to -$358.97M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.